IL2 and plasma cell myeloma: To provide additional support for the hypothesis that IL-2 contributes to elotuzumab-mediated NK cell-dependent myeloma cell killing, we examined myeloma cell co-cultures either with PBL or with purified NK cells in the presence of elotuzumab and an exogenous source of IL-2.